Search Results
Oct 29, 2025, 07:05 ET REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Oct 29, 2025, 07:00 ET Inari Appoints Lisa Nunez Safarian Chief Executive Officer
through its AI-enabled SEEDesign™ Platform – the industry's most sophisticated performance accelerator, integrating breakthroughs in genomics, AI and gene editing for exceptional seed designs. Safarian continued, "Inari is built on groundbreaking technology – from AI-enabled systems
More news about: Flagship Pioneering
Oct 29, 2025, 05:01 ET IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
leading Korean biotechnology company focused on immune cell therapies, including CAR-NK, CAR-T, and CIK cell platforms, and CDMO services for cell and gene therapy. With extensive expertise in manufacturing and commercialization of autologous and allogeneic cell therapies, GC Cell is expanding its global
More news about: IASO Bio
Oct 29, 2025, 02:59 ET MGI Tech Announces Exclusive Licensing Agreement with Swiss Rockets AG to Globalize Proprietary CoolMPS™ Sequencing Technology
after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI TECH
Oct 28, 2025, 17:31 ET CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight
gravis, and juvenile dermatomyositis. Interius BioTherapeutics' INT2104 is a fully owned investigational gene therapy that selectively targets CD7-positive T and NK cells, delivering a CAR transgene to generate effector CAR-T and CAR-NK cells in vivo. These
More news about: DelveInsight Business Research, LLP
Oct 28, 2025, 14:18 ET Cetera Financial Group Introduces Cetera Private Wealth Portfolios to Serve Affluent and High-Net-Worth Clients
Gene Goldman. Goldman said: "One example on how we see this fitting in a Cetera financial professional's arsenal is the ability
More news about: Cetera Financial Group
Oct 28, 2025, 11:19 ET Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex
More news about: Genprex, Inc.
Oct 28, 2025, 10:54 ET Invert launches Invert Assist, an AI-powered analysis interface built for bioprocess
corporate IT layers, and fragmented data workflows across scales and sites. Additionally, new therapeutic modalities such as complex biologics and cell and gene therapies bring even more complicated processes that require deeper insights. These challenges create an "analysis to action" gap, hindering bioprocess
More news about: Invert
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
Biotech. Tsingke's Perspective: From Gene Synthesis to Scalable Manufacturing As a full-stack Gene Factory, Tsingke Biotech demonstrated capabilities spanning DNA/RNA synthesis, antibody expression,
More news about: Beijing Tsingke Biotech Co., Ltd.
Oct 28, 2025, 10:47 ET Tsingke Biotech Showcased AI-Powered Biomanufacturing Solutions at 2025 Festival of Biologics
Manager of Tsingke Biotech. Tsingke's Perspective: From Gene Synthesis to Scalable Manufacturing As a full-stack Gene Factory, Tsingke Biotech demonstrated capabilities spanning DNA/RNA synthesis, antibody expression,
More news about: Beijing Tsingke Biotech Co., Ltd.
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC
"announc[ing] results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)." The press release disclosed that latozinemab "did not meet the clinical co-primary endpoint of slowing FTD-GRN progression,"
More news about: Pomerantz LLP
Oct 28, 2025, 08:30 ET Where Will Your CGT Study Go? Solving the Site Capacity Challenge, Upcoming Webinar Hosted by Xtalks
& Gene Therapy, Premier Research; Brittany Groner, Director, Clinical Operations, BridgeBio Gene Therapy;
More news about: Xtalks
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
R&D resources and efficiency enhancement. The Group has gradually built a high-value pipeline portfolio and deployed radiopharmaceuticals, RNA, gene therapy, AI drug R&D and other cutting-edge technologies in order to facilitate the R&D process. Meanwhile, Fosun Pharma continuously strengthens
More news about: Fosun Pharma
Oct 28, 2025, 08:06 ET Orchestra Life Sciences Relocates Global Headquarters to Philadelphia's Navy Yard
than 60 employees and consultants worldwide. Collectively, the team brings over 500 years of expertise in nuclear medicine and 100 years in cell and gene therapy, enabling clients to move therapies from concept to commercialization with confidence. "Relocating our headquarters to
More news about: Orchestra Life Sciences
Oct 28, 2025, 08:00 ET RheumaGen Presents HLA Gene-Editing Preclinical Data for Nearly Universal Autoimmune Disease Target at ACR Convergence 2025 Oral Session
RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics to cure common autoimmune diseases, today announced groundbreaking preclinical research that supports a nearly universal target for almost all of the company's human leukocyte antigen (HLA) gene-editing therapies. While
More news about: RheumaGen, Inc.
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 08:00 ET Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing
fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing support across gene therapy, APIs, and both large and small molecule manufacturing. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities
More news about: Ajinomoto Bio-Pharma Services
Oct 28, 2025, 07:00 ET Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) for the treatment
More news about: Genprex, Inc.
Oct 28, 2025, 03:45 ET Kanazawa University Research: Scanning nanoprobe microscope reveals the hidden flexibility of cancer cells
state. Chromatin compaction: The way DNA and proteins are tightly or loosely packed, affecting gene activity and nuclear mechanics. Histone H4K20me3: A chemical modification of histone proteins
More news about: Kanazawa University
Oct 27, 2025, 17:31 ET Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
Ongoing research into the genetic underpinnings of BCNS is facilitating the development of targeted therapies. Innovations such as gene editing and personalized medicine are offering new avenues for treatment, moving beyond traditional approaches to address the root causes of the syndrome.
More news about: DelveInsight Business Research, LLP
Oct 27, 2025, 16:07 ET Welltower Announces a Transformative New Era to Maximize Long-Term Shareholder Returns
class. All of them also share two rare genetic qualities: a 'delayed gratification' gene referring to their instinctive bias towards sacrificing an immediate reward for a much larger gain tomorrow and a 'fiduciary gene' representing their innate desire to put the interests of our owners ahead of their
More news about: Welltower Inc.
Oct 27, 2025, 16:03 ET BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
believe ROCTAVIAN has an important role to play in the treatment of hemophilia A and are therefore evaluating out-licensing options for this innovative gene therapy. This decision is consistent with BioMarin's portfolio strategy and offers the most promising opportunity for ensuring continued patient access
More news about: BioMarin Pharmaceutical Inc.
Oct 27, 2025, 14:08 ET Plastomics Announces Initial Close of Series B Financing to Advance Groundbreaking Corn Chloroplast Transformation Technology
sustainable." Plastomics' proprietary chloroplast engineering platform offers several game-changing advantages over conventional gene delivery, including: No Pollen Outcrossing: Chloroplasts are
More news about: Plastomics
Oct 27, 2025, 10:50 ET Global Optogenetics Equipment Market Valued at USD 400 Million in 2024, Projected to Reach USD 1.2 Billion by 2033, Growing at a 15.5% CAGR from 2026 to 2033 - Market Research Intellect
software. These factors collectively strengthen market growth and attract new players entering the field. With technological advancements in imaging and gene delivery systems, optogenetics is emerging as a cornerstone in modern neuroscience research, enabling scientists to explore neural pathways and brain
More news about: Market Research Intellect
Oct 27, 2025, 10:20 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
The partnership aims to enable precise and durable gene expression in target cell types relevant to Purespring's therapeutic strategy. While specific program details remain confidential, the project is designed to enhance the safety and efficacy of gene delivery through the integration of rationally designed
More news about: CHROMATIN BIOSCIENCE LTD